Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Mirapex (pramipexole) Clear all
Completed Phase 4 Interventional Results available

Targeting Cognition in Bipolar Disorder With Pramipexole

NCT02397837
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Glen Oaks, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Phase 4 Interventional Results available

Naltrexone for Impulse Control Disorders in Parkinson's Disease

NCT01052831
View directory record Official record
Conditions
Impulse Control Disorder, Parkinson Disease
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 3, 2026, 6:17 PM EDT
Active, not recruiting Phase 2 Interventional

Pramipexole to Enhance Social Connections

NCT06269146
View directory record Official record
Conditions
Anxiety Disorders, Anxiety, Depression, Social Disconnection
Interventions
Pramipexole Pill, Placebo Pill
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 3, 2026, 6:17 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
146
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Phase 4 Interventional Results available

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

NCT00144300
View directory record Official record
Conditions
Parkinson Disease
Interventions
Mirapex, Requip
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial of Pramipexole in Bipolar Depression

NCT00025792
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Pramipexole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 3, 2026, 6:17 PM EDT
Completed No phase listed Observational

Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)

NCT00617019
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years to 75 Years
Enrollment
3,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
36
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Sun City, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Dexpramipexole in ALS

NCT01281189
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
43
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 3, 2026, 6:17 PM EDT
Suspended Phase 2 Interventional

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

NCT06705478
View directory record Official record
Conditions
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
Interventions
Pramipexole ER, Escitalopram
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 3, 2026, 6:17 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Extension Study of Dexpramipexole in ALS

NCT01622088
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Phoenix, Arizona • Fresno, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Imaging Dopamine Release in Depression

NCT02033369
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Pramipexole
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Phase 1Phase 2 Interventional

R(+)PPX High Dose Treatment of ALS

NCT00600873
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
R(+) pramipexole dihydrochloride monohydrate
Drug
Lead sponsor
Bennett, James P., Jr., M.D., Ph.D.
Individual
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Oct 3, 2026, 6:17 PM EDT
Terminated Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

NCT05813288
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Phase 3 Interventional

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

NCT00335166
View directory record Official record
Conditions
Early Stage Parkinson Disease
Interventions
Pardaprunox, pramipexole, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Oceanside, California • Oxnard, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Phase 2 Interventional Results available

Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria

NCT00558467
View directory record Official record
Conditions
Tourette Syndrome
Interventions
pramipexole immediate release (IR), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
14
States / cities
Bradenton, Florida • Tampa, Florida • Columbus, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 3, 2026, 6:17 PM EDT
Terminated Phase 3 Interventional

Phase III Long-Term Extension Study With Dexpramipexole

NCT06388889
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Dexpramipexole Dihydrochloride
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Bakersfield, California • Northridge, California • Coral Gables, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 3, 2026, 6:17 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole

NCT01066897
View directory record Official record
Conditions
Depression
Interventions
Pramipexole
Drug
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 3, 2026, 6:17 PM EDT
Recruiting Phase 2 Interventional

Stratified Pharmacological Approaches for Regulating Circuit-Level Effects

NCT07022405
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Pramipexole Immediate Release
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)

NCT01511029
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Dexpramipexole Placebo, Moxifloxacin
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

NCT03329508
View directory record Official record
Conditions
Parkinson Disease, Early Parkinson's Disease
Interventions
P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
45
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Phase 4 Interventional Results available

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

NCT00402233
View directory record Official record
Conditions
Parkinson Disease
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
31 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Early Phase 1 Interventional Results available

Non-Opioid Pramipexole and Pain

NCT03842709
View directory record Official record
Conditions
Chronic Pain
Interventions
Pramipexole Oral Tablet, Placebo
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 3, 2026, 6:17 PM EDT
Withdrawn Phase 4 Interventional

Butrans for Treatment of Restless Legs Syndrome

NCT02138357
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 3, 2026, 6:17 PM EDT
Completed Phase 4 Interventional

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

NCT00344994
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
pramipexole
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 3, 2026, 6:17 PM EDT